The randomized phase II DESTINY-Gastric01 trial in Asia demonstrated that T-DXd as third- or later-line therapy significantly improved objective response rate (ORR) and overall survival (OS), compared with those of the physician’s choice of chemotherapy, among previously treated patients with HER2-positive gastric cancer or gastroesophageal junction cancer (GC/GEJC) [2]. Here, ERBB2 is linked to gastric cancer.